RESUMO
Gene therapy is becoming increasingly prevalent, with new gene therapy medicinal products (GTMPs) being approved for use every year. Hospital pharmacists are expected to prepare and dispense these products, but there is substantial heterogeneity in the availability of up-to-date, practical guidance at a national level in Europe. Many institutions have no or very limited experience in handling GTMPs. As such, there is a need for updated, practical guidance to aid hospital pharmacy teams in developing institutional standard operating procedures (SOPs) for the safe handling of GTMPs across the entire workflow. Here, we present the European Association of Hospital Pharmacists' updated guidance on the handling of GTMPs, developed by a team of recognised experts from around Europe. Each aspect of the GTMP handling process is addressed, including receipt and storage, dispensing and reconstitution, transportation, administration, waste disposal, decontamination of spills and accidental exposure. A series of figures are provided to aid the development of practical workflows. This guidance document is intended as a framework to help develop institutional SOPs and should always be used in conjunction with local regulations.
Assuntos
Terapia Genética , Farmacêuticos , Serviço de Farmácia Hospitalar , Serviço de Farmácia Hospitalar/normas , Serviço de Farmácia Hospitalar/métodos , Humanos , Farmacêuticos/normas , Europa (Continente) , Terapia Genética/métodos , Terapia Genética/normas , Sociedades Farmacêuticas/normasRESUMO
National pharmacy associations have increasingly explored regulation according to a "standard of care." In such a model, pharmacists can provide a wide range of clinical services aligned with their education and training. Based on Idaho's experience implementing this model, there are five critical steps states must take to enact a standard of care: 1) Adopt a broad definition of "practice of pharmacy;" 2) Allow elasticity for practice innovation over time; 3) Decide which limited instances still necessitate prescriptive regulation; 4) Eliminate all unnecessary regulations; and 5) Strengthen accountability for deviations from the standard of care. States wishing to adopt a standard of care approach can follow this five-step process to enhance patient care and mitigate the lag that is otherwise constant between laws and practice.
Assuntos
Farmacêuticos , Padrão de Cuidado , Farmacêuticos/legislação & jurisprudência , Farmacêuticos/normas , Humanos , Padrão de Cuidado/legislação & jurisprudência , Assistência Farmacêutica/legislação & jurisprudência , Assistência Farmacêutica/normas , Assistência Farmacêutica/organização & administração , Papel Profissional , Idaho , Sociedades Farmacêuticas/normas , Assistência ao Paciente/normasRESUMO
In May 2020, the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) published a recommendation report entitled "Recommendation on nonanimal-derived antibodies". In this report, the EURL ECVAM specifically states: "Therefore, taking into consideration the ESAC Opinion on the scientific validity of replacements for animal-derived antibodies, EURL ECVAM recommends that animals should no longer be used for the development and production of antibodies for research, regulatory, diagnostic and therapeutic applications. The provisions of Directive 2010/63/EU should be respected, and EU countries should no longer authorise the development and production of antibodies through animal immunisation, where robust, legitimate scientific justification is lacking." (1). Here, we are providing the American Association of Pharmaceutical Scientists (AAPS) opinion on the EURL ECVAM recommendation report. In brief, there has been a clear and strong progress in reduction of animal use in the drug discovery and development process, including significant reduction of animal use in production of antibody reagents. Yet, it is proposed that more data need to be generated, shared and discussed within the scientific community before a decision to implement the change to non-animal derived antibodies is made.
Assuntos
Alternativas ao Uso de Animais/normas , Anticorpos Monoclonais/isolamento & purificação , Farmácia/normas , Sociedades Farmacêuticas/normas , Tecnologia Farmacêutica/normas , Animais , Anticorpos Monoclonais/genética , Anticorpos Monoclonais/uso terapêutico , União Europeia , Políticas , Proteínas Recombinantes/genética , Proteínas Recombinantes/isolamento & purificação , Proteínas Recombinantes/uso terapêutico , Tecnologia Farmacêutica/métodos , Estados UnidosRESUMO
PURPOSE: This report describes the development and maintenance of a table to present an assessment of evidence for treatments used in patients with coronavirus disease 2019 (COVID-19). SUMMARY: AHFS Drug Information (AHFS DI) (American Society of Health-System Pharmacists, Bethesda, MD) is ASHP's evidence-based drug compendium that contains drug monographs written for pharmacists and other healthcare professionals. The professional editorial and analytical staff of pharmacists critically evaluate published evidence to develop drug monographs for AHFS DI. In response to the global COVID-19 pandemic, these skills were applied to assess emerging evidence for COVID-19-related treatments, and the information was compiled into a new resource for pharmacists and other healthcare professionals to use at the point of care. A list of therapies was developed and prioritized based on review of scientific and public discussions on the use of these therapies in patients with COVID-19; certain therapies used for supportive care and therapies that might theoretically be harmful to patients with COVID-19 also were considered for inclusion. Potential treatments were identified, and the evidence for use in patients with COVID-19 was assessed and summarized in a table format. Information presented for each therapy included the rationale for use, summaries of clinical trials or experience, trial registry numbers, and dosage regimens. Comments on safety and efficacy, including limitations of available data, were presented along with recommendations from recognized authorities. The editorial team continued to add new therapies to the table and update existing entries as new evidence emerged. CONCLUSION: A comprehensive table that summarized available evidence for potential treatments for patients with COVID-19 was developed. The table format enabled the drug information editorial staff to provide ongoing updates as new information emerged during the pandemic.
Assuntos
COVID-19/terapia , Prática Farmacêutica Baseada em Evidências/métodos , Farmacêuticos , Sociedades Farmacêuticas , Estatística como Assunto/métodos , Antivirais/administração & dosagem , Antivirais/classificação , COVID-19/epidemiologia , Ensaios Clínicos como Assunto/métodos , Ensaios Clínicos como Assunto/normas , Prática Farmacêutica Baseada em Evidências/normas , Humanos , Farmacêuticos/normas , Sociedades Farmacêuticas/normas , Estatística como Assunto/normas , Estados Unidos/epidemiologiaAssuntos
Organizações de Planejamento em Saúde/tendências , Farmacêuticos/tendências , Projetos de Pesquisa/tendências , Sociedades Farmacêuticas/tendências , Organizações de Planejamento em Saúde/normas , Humanos , Farmacêuticos/normas , Projetos de Pesquisa/normas , Sociedades Farmacêuticas/normasRESUMO
DISCLOSURES: No funding was required for this project. The authors are or have been members of the Format Executive Committee.
Assuntos
Documentação/normas , Medicina Baseada em Evidências/normas , Programas de Assistência Gerenciada/normas , Farmacopeias como Assunto/normas , Sociedades Farmacêuticas/normas , Tomada de Decisões Gerenciais , Custos de Medicamentos/normas , Medicina Baseada em Evidências/economia , Medicina Baseada em Evidências/organização & administração , Programas de Assistência Gerenciada/economia , Programas de Assistência Gerenciada/organização & administração , Uso Off-Label/economia , Uso Off-Label/normas , Estados UnidosRESUMO
BACKGROUND: Improved knowledge of the molecular pathophysiology and immunopathogenesis of cholestatic liver diseases in recent years has led to an increased interest in developing novel therapies. Patients with cholestatic liver disease often require different approaches to assessment and management of suspected drug-induced liver injury (DILI) compared to those with healthy livers and those with parenchymal liver diseases. At present, there are no regulatory guidelines or society position papers, that systematically address best practices pertaining to detection of DILI in these patients. AIMS: To outline best practices for detection, assessment and management of suspected acute DILI during clinical trials in adults with the cholestatic liver diseases - Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC). METHODS: This is one of the several papers developed by the IQ DILI Initiative, which is comprised of members from 16 pharmaceutical companies, in collaboration with DILI experts from academia and regulatory agencies. The contents are the result of an extensive literature review, as well as in-depth discussions among industry, regulatory and academic DILI experts, to achieve consensus recommendations on DILI-related issues occurring during clinical trials for cholestatic liver diseases. RESULTS: Recommended best practices are outlined pertaining to hepatic eligibility criteria, monitoring of liver tests, approach to a suspected DILI signal, and hepatic discontinuation rules. CONCLUSIONS: This paper provides a framework for the approach to detection, assessment and management of suspected acute DILI occurring during clinical trials in adults with cholestatic liver disease.
Assuntos
Doença Hepática Induzida por Substâncias e Drogas/diagnóstico , Doença Hepática Induzida por Substâncias e Drogas/terapia , Colestase/tratamento farmacológico , Ensaios Clínicos como Assunto , Consenso , Cirrose Hepática Biliar/tratamento farmacológico , Adulto , Doença Hepática Induzida por Substâncias e Drogas/patologia , Colestase/patologia , Doença Crônica , Ensaios Clínicos como Assunto/estatística & dados numéricos , Indústria Farmacêutica/organização & administração , Indústria Farmacêutica/normas , Humanos , Fígado/efeitos dos fármacos , Fígado/patologia , Fígado/fisiopatologia , Cirrose Hepática Biliar/patologia , Testes de Função Hepática , Sociedades Farmacêuticas/normasRESUMO
PURPOSE: To describe a process to identify metrics that represent the impact of inpatient pharmacy services on patient outcomes across a health system. SUMMARY: The authors describe a systematic process of identifying inpatient clinical outcome measures that could represent pharmacists' impact on patient outcomes and eventually be displayed in a dashboard within the electronic medical record (EMR). A list was generated through literature review, assessment of practices at other sites, evaluation of current pharmacy services, and collaboration with the quality department and System Pharmacy Clinical User Group. The project team narrowed the list through assessment against standardized criteria. An assessment tool was designed and distributed to stakeholders to prioritize clinical outcome measures for inclusion on the dashboard. The clinical outcome measures were transformed into metrics by determining measurement criteria, inclusion and exclusion parameters, and review time frame. After validation, the metrics are planned to be displayed on an inpatient pharmacy EMR dashboard. Exemption from institutional review board review was granted for this project. CONCLUSION: A systematic process was developed and used to identify inpatient clinical outcome metrics.
Assuntos
Benchmarking/organização & administração , Avaliação de Resultados em Cuidados de Saúde/normas , Serviço de Farmácia Hospitalar/organização & administração , Indicadores de Qualidade em Assistência à Saúde/normas , Benchmarking/normas , Registros Eletrônicos de Saúde/estatística & dados numéricos , Estudos de Viabilidade , Implementação de Plano de Saúde , Humanos , Modelos Organizacionais , Serviço de Farmácia Hospitalar/normas , Sociedades Farmacêuticas/normas , Estados UnidosAssuntos
Assistência Perioperatória/normas , Serviço de Farmácia Hospitalar/normas , Sociedades Farmacêuticas/normas , Análise Custo-Benefício , Planos de Pagamento por Serviço Prestado , Humanos , Conduta do Tratamento Medicamentoso/economia , Conduta do Tratamento Medicamentoso/normas , Assistência Perioperatória/economia , Serviço de Farmácia Hospitalar/economia , Estados Unidos , Seguro de Saúde Baseado em ValorAssuntos
Educação em Farmácia/normas , Legislação Farmacêutica/normas , Técnicos em Farmácia/educação , Sociedades Farmacêuticas/legislação & jurisprudência , Acreditação/normas , Educação em Farmácia/legislação & jurisprudência , Educação em Farmácia/tendências , Humanos , Legislação Farmacêutica/tendências , Licenciamento/normas , Sociedades Farmacêuticas/normas , Estados UnidosAssuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle , Farmácias/organização & administração , Farmácias/normas , Insuficiência Renal Crônica/diagnóstico , Insuficiência Renal Crônica/etiologia , Insuficiência Renal Crônica/prevenção & controle , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , França/epidemiologia , Humanos , Doença Iatrogênica/epidemiologia , Doença Iatrogênica/prevenção & controle , Programas de Rastreamento/métodos , Programas de Rastreamento/normas , Guias de Prática Clínica como Assunto , Padrões de Prática Médica/normas , Padrões de Prática Médica/estatística & dados numéricos , Insuficiência Renal Crônica/epidemiologia , Fatores de Risco , Sociedades Farmacêuticas/organização & administração , Sociedades Farmacêuticas/normasRESUMO
Reliable results of pharmacokinetic and toxicokinetic studies are vital for correct decision making during drug discovery and development. Thus, ensuring high quality of bioanalytical methods is of critical importance. Incurred sample reanalysis (ISR)-one of the tools used to validate a method-is included in the bioanalytical regulatory recommendations. The methodology of this test is well established, but the estimation of the sample size is still commented on and contested. We have applied the hypergeometric distribution to evaluate ISR test passing rates in different clinical study sizes. We have tested both fixed rates of the clinical samples-as currently recommended by FDA and EMA-and a fixed number of ISRs. Our study revealed that the passing rate using the current sample size calculation is related to the clinical study size. However, the passing rate is much less dependent on the clinical study size when a fixed number of ISRs is used. Thus, we suggest using a fixed number of ISRs, e.g., 30 samples, for all studies. We found the hypergeometric distribution to be an adequate model for the assessment of similarities in original and repeated data. This model may be further used to optimize the sample size needed for the ISR test as well as to bridge data from different methods. This paper provides a basis to re-consider current ISR recommendations and implement a more statistically rationalized and risk-controlled approach.
Assuntos
Ensaios Clínicos como Assunto/métodos , Modelos Estatísticos , Controle de Qualidade , Estudos de Validação como Assunto , Ensaios Clínicos como Assunto/normas , Ensaios Clínicos como Assunto/estatística & dados numéricos , Humanos , Reprodutibilidade dos Testes , Tamanho da Amostra , Sociedades Farmacêuticas/normas , Estados Unidos , United States Food and Drug Administration/normasRESUMO
The Safety Pharmacology Society organized a scientific session at its annual conference in 2017 to discuss the challenges and opportunities of the Comprehensive In-Vitro Proarrhythmia Assay (CiPA) paradigm. Our intention was to raise awareness of this initiative with its members and also to gauge the extent to which safety pharmacologists have incorporated the CiPA testing strategy within the pharmaceutical industry. CiPA offers many potential opportunities including 1) a focus on proarrhythmic risk (as opposed to QTc prolongation), 2) providing scientific rationale to support the continued development of compounds that may have a poor selectivity over hERG whilst also blocking other inward currents and 3) reducing the extent of ECG monitoring in clinical trials with a greater influence of the non-clinical studies. Such opportunities may speed drug development and reduce costs. However, there are also challenges for CiPA implementation. For example, the mixed ion channel paradigm does not easily lend itself to a prospective drug discovery strategy although testing for such effects can be achieved with assays with good throughput. However, it should also be recognized that compounds with a mixed ion channel profile might also have properties that are undesirable to treat non-life threatening indications. All components of CiPA (nonclinical and clinical) require validation, particularly as a composite package to impact drug development and evaluation. One of the significant discussion points was that the existing regulatory guidance supports the use of components of CiPA through follow-up studies. A survey of the conference audience showed that the level of awareness of CiPA is quite high and that companies are already conducting some testing against a wider panel of cardiac ion channels beyond hERG. However, the adoption of other technologies (stem cell derived cardiac myocytes and in silico modeling) is less well developed. Taken together, the session demonstrated the potential advantages of CiPA, but also some significant challenges.